691 (Divalproex Sodium Extended-Release 250 mg)

Pill imprint 691 has been identified as Divalproex sodium extended-release 250 mg.

Divalproex sodium is used in the treatment of bipolar disorder; mania; migraine prevention; epilepsy; borderline personality disorder (and more), and belongs to the drug class fatty acid derivative anticonvulsants. When treating epilepsy and manic episodes associated with bipolar disorder: There is positive evidence of human fetal risk during pregnancy. When treating migraine: Not for use in pregnancy. Divalproex sodium 250 mg is not a controlled substance under the Controlled Substance Act (CSA).

Divalproex sodium extended-release

Imprint:

691

Strength:

250 mg

Color:

White

Size:

6.00 mm

Shape:

Capsule-shape

Availability:

Prescription only

Drug Class:

Fatty acid derivative anticonvulsants

Pregnancy Category:

D - Positive evidence of risk - When treating epilepsy and manic episodes associated with bipolar disorder
X - Not for use in pregnancy - When treating migraine

CSA Schedule:

Not a controlled drug

Manufacturer:

Global Pharmaceuticals

National Drug Code (NDC):

00115-6911

Inactive Ingredients:

silicon dioxide
copovidone
calcium phosphate dihydrate dibasic
hydrogenated cottonseed oil
hypromellose
polyethylene glycol
polyvinyl alcohol
magnesium silicate
titanium dioxide
microcrystalline cellulose
stearic acid
xanthan gum

Note: Inactive ingredients may vary.

More info Print Imprint Search

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Copyright 2017 Drugs.com, National Library of Medicine, Truven Health Analytics and Cerner Multum, Inc. All Rights Reserved.